
Imugene Investor Relations Material
Latest events

EGM 2025
Imugene
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Imugene Limited
Access all reports
Imugene Limited is an Australian biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered around activating the immune system to target and eliminate cancer cells, utilizing a range of technologies, including oncolytic viruses and B-cell activating immunotherapies. Imugene’s clinical pipeline includes treatments for various cancer types, and the company works on advancing its therapies through preclinical and clinical development stages. The company is headquartered in Sydney, Australia, and its shares are listed on the ASX.
Key slides for Imugene Limited


AGM 2024
Imugene Limited


AGM 2024
Imugene Limited
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
IMU
Country
🇦🇺 Australia